The Global Health Body Issues Alert Over Critical Scarcity of Weight-Loss Injections
Less than 10% of individuals who could benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it releases its initial advice on the medications.
Given in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The new guidance recognises that excess weight is a lifelong illness that can be treated with comprehensive and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are key barriers to universal access to the injections that can assist patients in reducing substantial body mass, notes the agency.
Skinny Jab Supply Crisis
Despite the present most favorable scenario, the supply of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The advice encourages governments and firms to expand access, by strategies including patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several nations in 2026.
The Way Weight-Loss Injections Work
These medications replicate a body's own hormone to slow digestion, suppress the appetite and enhance satiety so people eat less.
People commonly start to lose weight in the initial weeks of starting on the once-weekly jabs.
Research points to patients may regain a significant portion after a year of stopping the drug, when their typical food cravings return.
Being overweight or obese raises your likelihood for developing health problems, including diabetes, heart disease, stroke, and some malignancies.
Excess weight affects individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.